文献速递核素与放射性配体治疗肿瘤 PET/CT

转移性去势抵抗性前列腺癌患者重复177Lu-PSMA-617放射性配体治疗后的延迟缓解

Delayed response after repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2017-11-13

这项回顾性研究分析了71例接受3个周期177Lu-PSMA-617放射性配体治疗的转移性去势抵抗性前列腺癌患者,每8周给药一次,平均给药活度6.016±0.543 GBq。56%的患者出现PSA下降≥50%,66%出现任何PSA下降;首周期有PSA反应的30例中28例后续仍为反应者,41例无反应者中12例在后续周期出现反应。

要点

  • 56%的患者出现PSA下降≥50%,66%出现任何PSA下降。
  • 首周期有反应的30例中28例后续仍为反应者。
  • 41例首周期无反应者中12例在后续治疗周期出现反应。

核心结论

  • 177Lu-PSMA-617放射性配体治疗显示出可观的缓解率,本回顾性分析中相当数量患者出现延迟缓解,即使首周期治疗无反应。

研究设计与样本

  • 回顾性研究,纳入71例接受3个周期177Lu-PSMA-617放射性配体治疗的转移性去势抵抗性前列腺癌患者,中位年龄72岁(范围44-87岁),每8周给药一次,平均给药活度6.016±0.543 GBq。

主要发现

  • 71例患者共完成213个治疗周期,所有患者均有缓解和不良事件数据。
  • 56%的患者出现PSA下降≥50%,66%的患者出现任何PSA下降。
  • 首周期有PSA反应的30例患者中,28例后续仍为反应者。
  • 首周期无PSA反应的41例患者中,12例在后续治疗周期出现反应。

关键数值与推荐

  • 生化反应定义为血清PSA下降≥50%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Radioligand therapy (RLT) using Lutetium-177 labeled PSMA-617 (Lu-PSMA) ligand is a new therapeutic option for salvage therapy in heavily pretreated patients with metastatic castration resistant prostate cancer. The aim of this retrospective study was to analyze response in patients receiving 3 cycles of Lu-PSMA. METHODS: Seventy-one patients (median age: 72 years; range 44-87) received 3 cycles of RLT with Lu-PSMA (mean administered activity: 6.016 ± 0.543 GBq) every 8 weeks. Response was evaluated using serum PSA levels and a PSA decline ≥50% was considered as biochemical response. Additionally, any PSA decline after the first cycle was evaluated for further therapy effects after the second and third cycle. RESULTS: A total of 213 cycles were performed in 71 patients. Data for response and adverse events were available for all patients. A PSA decline ≥50% and some PSA decline occurred in 56% and 66% of the patients. Of 30 patients with a PSA response after the first cycle, 28 remained responders and 12/41 of non-responders responded to further therapy cycles. CONCLUSION: RLT with Lu-177-PSMA-617 shows respectable response rates. In this retrospective analysis, a relevant number of patients showed a delayed response, even if they did not respond to the first cycle of the therapy.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Rahbar K, Bögeman M, Yordanova A, et al. Delayed response after repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2017. PMID: 29134280. doi:10.1007/s00259-017-3877-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。